First AD

Second AD

CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

The Expanding Role of CAR T Cells in Lymphoma and Leukemia

Peer Exchange

The Importance of Antigen Loss in R/R Disease

Rationale for Further Development of CAR T-Cell therapy

CAR T-Cell Therapy in Managing Various Lymphomas

R/R Large B-Cell Therapy in Managing Various Lymphomas

Liso-cel Therapy in R/R Large B-Cell Lymphoma

LDH and ECOG Performance Tests

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact 

CAR T-Cell Therapy for Follicular Lymphoma

R/R NHL: Candidate Identification and Referrals

LBCL Therapy: The Right Therapy

CAR T Cells and Lymphoma Adverse Events

CAR T-Cell Therapy’s Future for Lymphoma

Allogenic CAR T-Cell Therapy in Lymphoma

Developing CAR T-Cell Trials

Ongoing Issues in CAR T-Cell Therapy and Lymphoma